Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey
BMC INFECTIOUS DISEASES, vol.13, 2013 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 13
- Publication Date: 2013
- Doi Number: 10.1186/1471-2334-13-560
- Journal Name: BMC INFECTIOUS DISEASES
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Keywords: Antifungal agents, Voriconazole, Liposomal amphotericin B, Economic evaluation, Invasive fungal infection, Empiric therapy, ANTIFUNGAL THERAPY, FEBRILE NEUTROPENIA, ECONOMIC-EVALUATION, PERSISTENT FEVER, CASPOFUNGIN, IMPACT
- Eskisehir Osmangazi University Affiliated: Yes
Abstract
Background: Invasive fungal infections (IFI) are associated with considerable expense and mortality on healthcare systems. There is a need to provide evidence of both clinical efficacy and value for money with any health technology. The current pharmacoeconomic evaluation investigated the use of liposomal amphotericin B (LAmB) and voriconazole for the empiric treatment of IFI in the Turkish setting.